Epizyme Inc. (NASDAQ:EPZM) fell $2.30 (15%) to $13 in afternoon trading Tuesday after reporting late Monday that FDA placed a partial clinical hold on tazemetostat (E7438, EPZ-6438). The move shaved $160 million off the company’s market cap.
The hold was placed in response to a report of a patient who developed secondary T cell lymphoma during a Phase I pediatric trial of tazemetostat, a selective inhibitor of enhancer of zeste homolog 2 (EZH2) (see BioCentury Extra, April 23).